Immunepharma.com
| Top immune sites |
| Top pharma sites |
- Title
- Immune Pharmaceuticals
- Meta Description
- Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP; OTCQX: IMNP,) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in ...
- Meta Keywords
- Technologies in use
- WordPress, Google Analytics, jQuery, FastClick, twemoji, Font Awesome
| Cache-Control | public, max-age=600 |
| Content-Encoding | gzip |
| Content-Type | text/html; charset=U |
| Server | nginx |
| Surrogate-Key | ELaTshlTyVFRkOB/Golk |
| Surrogate-Key-Raw | |
| X-Pantheon-Endpoint | 033f22c6-34cf-4848-b |
| X-Pantheon-Styx-Hostname | styxf8f66dba |
| X-Styx-Req-Id | styx-1ecd56dd4f1f59b |
| X-Styx-Version | StyxGo |
| xkey | ELaTshlTyVFRkOB/Golk |
| X-Varnish | 554622093 |
| Age | 0 |
| Via | 1.1 varnish-v4 |
| Vary | Accept-Encoding, Coo |
| Accept-Ranges | bytes |
| Transfer-Encoding | chunked |
| Connection | keep-alive |